Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.
Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.
Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.
Echoliv is a medical technology company specializing in artificial intelligence solutions for abdominal ultrasound. The company develops software designed to assist radiologists and hepatologists in early-stage screening for hepatocellular carcinoma, the most common type of liver cancer. Echoliv's flagship product, Ultraliv, employs advanced algorithms to identify nodules that may be overlooked by practitioners, enhancing diagnostic accuracy and improving patient care. By integrating AI into the ultrasound process, Echoliv aims to support healthcare professionals in delivering timely and effective treatment for liver cancer.
Get rid of electronics struggles thanks to an open source architecture to turn electronics devices and subsets as microservices.
Adeunis designs, manufactures, and markets connected objects and Internet of Things (IoT) solutions for various sectors, including smart buildings, industrial optimization, and connected agriculture. The company offers a range of products, such as radio frequency transmission modules, wireless transmission systems, and telemetry systems, tailored to meet the specific needs of its customers. Adeunis also provides services like on-site radio mapping, deployment, training, and data processing to support the management of buildings and infrastructure. Based in Crolles, France, the company focuses on creating customized radio solutions and ready-to-use systems that enhance connectivity and efficiency across multiple applications.
C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options.
To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.
OncoDiag is a French biotechnology company located in Normandy, dedicated to creating non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, the Urotest, is a urine test approved for the diagnosis and monitoring of bladder cancer. In addition to the Urotest, OncoDiag is developing Colodiag, a test focused on the early identification of colorectal cancer, and other diagnostic tools, including a tissue-based test for predicting non-evolutive localized prostate cancer. Through its innovative testing kits, OncoDiag aims to enhance cancer diagnostics, allowing healthcare professionals to provide timely and effective patient care.
Get rid of electronics struggles thanks to an open source architecture to turn electronics devices and subsets as microservices.
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.
ByBr operates a mobile application that facilitates the connection between consumers and brands through a simple interface that allows users to either type or scan brand names or logos. The app provides immediate access to localized official information, including websites, social media links, contact details, and messaging options, allowing for effortless interaction. Additionally, ByBr serves as an online platform for influencer and brand marketing, enabling brands to discover and collaborate with influential creators worldwide. This marketplace streamlines the process of communication and campaign management, while also ensuring secure payment methods for both brands and influencers. ByBr aims to enhance consumer engagement with brands and provide a seamless experience for users and marketers alike.
Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.
Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
Quantum Surgical is a provider of surgical robotics focused on developing innovative solutions for minimally invasive surgeries. The company is creating a novel robotic platform designed to enhance the assessment, planning, and treatment of medical conditions. Its technology supports advanced percutaneous ablation therapy, particularly for liver cancer treatment, aiming to improve patient outcomes and enhance the safety of interventional oncology procedures. With a commitment to delivering effective clinical solutions, Quantum Surgical seeks to represent unique spinal products and treatment options, benefiting both physicians and patients throughout the continuum of care.
Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.
Vulkam SAS, a micro technology company, engages in the design, development, and production of amorphous metal parts. The company’s amorphous metals are primarily composed of zirconium, copper, hafnium, nickel, or titanium. Its products have applications in aerospace, automotive, biomedical, cryogenic, watches, jewellery, micro components, and micro fluids industries. Vulkam SAS was founded in 2017 and is based in Saint-Martin-d'Hères, France.
TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Peculium is a cryptocurrency savings management platform based in Nanterre, France. It utilizes automatic machine learning to provide a transparent and efficient savings solution for users. The platform focuses on advanced wealth management and investment services, catering to clients who seek innovative ways to manage their cryptocurrency assets. By combining technology with financial expertise, Peculium aims to enhance the savings experience in the digital currency space.
SKIPPER NDT is the solution for improving the integrity of unpiggable pipelines. The continuous R&D efforts deployed by SKIPPER NDT allow us to boost the performance of the technology and extend the field of application, also to offshore pipelines.
TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.
Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.
At Ascendance we are building tomorrow’s flying taxi: Atea, a unique Vertical Take-Off and Landing (VTOL) aircraft with a hybrid propulsion system. We believe that the future of mobility will include the sky and that operational fit will be key to support the emergence of this market. Therefore we focused our efforts in designing an innovative, safe, silent, clean and affordable aircraft that will be able to blend into existing infrastructures and regulations to ease its deployment and maximise social acceptance.
Capte develops, produces and integrates smart IOT solutions for transportation.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Eversend SAS, founded in 2017 and based in Paris, France, offers a multi-currency e-wallet application that enables users to send and receive money, buy cryptocurrency, create virtual cards, and purchase airtime. The platform leverages blockchain technology to provide a digital payment gateway, facilitating electronic money transfers to bank accounts and mobile payments while minimizing costs associated with fees and foreign exchange. In addition to its current services, Eversend plans to expand its offerings to include personal loans, savings, group savings, merchant payments, and investment options. The company aims to grow its presence in Nigeria, Francophone Africa, and Europe while utilizing funds for product development, user acquisition, and regulatory compliance.
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.
Internest is a developer of a precise positioning system designed for rotating winged vehicles. The company's system utilizes a local landing system which is an embedded system with firmware and hardware to provide robust and accurate positioning information for all visibility, weather and environment, enabling security companies, military and maritime companies to assist drones and helicopters in their critical operations to improve flight safety.
VeriCampus specializes in enhancing student support for colleges and universities through the use of artificial intelligence. The company develops AI-powered chatbots, known as 'Campus Assistants,' which are designed to embody the character and knowledge of the institution. These chatbots assist students in navigating their college experience more effectively. Additionally, VeriCampus offers a messaging platform that aims to make education more accessible and affordable. This platform provides educational institutions with the necessary products, services, and information to facilitate student success and improve engagement across various aspects of the educational process. By focusing on personalized service at a lower cost, VeriCampus empowers schools to enhance the overall student experience.
Developer of an interactive animation-based application intended to offer instruments to let kids understand valuable things. The company's application stimulates creativity and logic, and offers a range of kid games, enabling kids to interact, coordinate and recognize through cartoon series, interactive cartoons, mini-games, and episodes.
Conscious Labs is a technology company focused on developing brain-computer interface (BCI) solutions that enhance human-tech interactions. The company creates wearable devices designed to collect raw data on brain activity in real-life settings. This innovative approach allows electronics manufacturers and startups to integrate BCI technology into products such as earphones and headsets. By facilitating a deeper understanding of brain functions, Conscious Labs aims to promote empathy in technology use and improve user experiences.
Seamless Waves is a fabless semiconductor company that specializes in designing and implementing reconfigurable RF transceivers. These advanced transceivers can sweep the frequency spectrum to identify the least occupied frequency bands, facilitating efficient communication through the appropriate wireless standards. Utilizing highly efficient RF Analog-to-Digital converters, Seamless Waves' technology ensures low power consumption, making it ideal for portable devices. In addition to its transceiver solutions, the company offers silicon-proven Analog/RF Physical Intellectual Property (IP) and virtual component models that support early system integration for clients.
Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.
Omind Neurotechnologies, founded in 2016 and based in Paris, France, specializes in developing neuro-technologies aimed at enhancing brain plasticity to better adapt to contemporary life. The company focuses on creating applications that facilitate the tracking, measurement, and training of brain functions, with an emphasis on emotional management, cognitive performance, and self-awareness. Its offerings include stress assessment tools, personalized analysis, and stress management training delivered in a virtual reality setting. Additionally, Omind develops neurotraining services, a normative multimodal database, and platforms that support real-time multimodal signal processing. The team comprises 19 members, including nine Ph.D. holders, who contribute to the company's intellectual property, trade secrets, and open science publications in the field of neurotechnology.
Polywed is a Healthcare IT company developing the data-driven technology that increases in vitro fertilization (IVF) success rates. Today average IVF live birth rate is about 30%. BioChron technology doubles the efficiency of the treatment up to 60%.
Connected Cycle offers innovative and cost-effective geolocation solutions tailored for both bikes and industrial assets. Full range portfolio from sensor to fleet management platform.
Ledger develops security and infrastructure solutions for cryptocurrencies as well as blockchain applications for individuals and companies, by leveraging a distinctive, proprietary technology. Launched in 2014, Ledger has designed an acclaimed line of hardware security devices quickly placing the company as a global leader on the market with 1,000,000 units sold in more than 165 countries. For enterprises and corporations, Ledger introduced the Vault: a fully managed SaaS solution addressing the need to safeguard a very large amount of multiple cryptocurrencies while mitigating both IT and physical assault threats. The company is also active on the industrial IoT market, leveraging its secure hardware technology to interface sensors and machines to smart contracts or blockchain based assets. Ledger is headquartered in Paris, has a production facility in Vierzon (France) and offices in San Francisco.
Qemotion is a company that specializes in sentiment analysis, offering a platform designed to convert emotions into actionable feedback. By utilizing artificial intelligence and predictive emotional technology, Qemotion analyzes the emotions expressed in various customer interactions, such as reviews, surveys, and social media comments. This comprehensive approach allows businesses to gain valuable insights into customer sentiments and employee opinions, ultimately enhancing customer experience, loyalty, and engagement. The platform serves as a bridge between raw emotional data and practical insights, enabling organizations to make informed decisions based on the feelings and experiences of their customers and employees.
Antabio SAS is a biopharmaceutical company based in Labège, France, focused on developing drugs to combat antibiotic-resistant bacterial infections. Established in 2009, the company specializes in creating inhibitors that target bacterial metalloenzymes to restore the efficacy of existing antibiotics against critical pathogens. Among its key developments are a Metallo Beta-Lactamase inhibitor designed to enhance carbapenem treatment, a Serine Beta-Lactamase inhibitor with broad coverage against key enzymes, and Pseudomonas Elastase inhibitors, which aim to reduce the frequency and severity of exacerbations in patients with Pseudomonas infections. Antabio's innovative approach addresses significant unmet medical needs in the fight against nosocomial infections, particularly those caused by drug-resistant bacteria.
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires
TheraVectys SAS is a biotechnology company based in Paris, France, focused on developing a novel lentiviral vector platform for T-cell vaccines aimed at addressing critical unmet medical needs. Established in 2005, the company specializes in vaccines for the treatment and prevention of infectious diseases, virally-induced cancers, and other medical conditions. TheraVectys is currently advancing its lead product, a therapeutic vaccine for HIV/AIDS, which has demonstrated promising efficacy and safety in preclinical studies involving non-human primates. The company's technology is designed to modulate the immune response through gene transfer into dendritic cells, facilitating the development of both prophylactic and therapeutic immunotherapies.
Connected Cycle offers innovative and cost-effective geolocation solutions tailored for both bikes and industrial assets. Full range portfolio from sensor to fleet management platform.
Antabio SAS is a biopharmaceutical company based in Labège, France, focused on developing drugs to combat antibiotic-resistant bacterial infections. Established in 2009, the company specializes in creating inhibitors that target bacterial metalloenzymes to restore the efficacy of existing antibiotics against critical pathogens. Among its key developments are a Metallo Beta-Lactamase inhibitor designed to enhance carbapenem treatment, a Serine Beta-Lactamase inhibitor with broad coverage against key enzymes, and Pseudomonas Elastase inhibitors, which aim to reduce the frequency and severity of exacerbations in patients with Pseudomonas infections. Antabio's innovative approach addresses significant unmet medical needs in the fight against nosocomial infections, particularly those caused by drug-resistant bacteria.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.